Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Overskridelsesundersøgelse for deltagere, der har gennemført en tidligere klinisk undersøgelse med benralizumab (Fasenra) og drager fordel af fortsat behandling (ROSY-F)

12. november 2026 opdateret af: AstraZeneca

ROSY-F: Roll-Over-undersøgelse for deltagere, der har gennemført en tidligere undersøgelse med Benralizumab (Fasenra) og som af undersøgeren vurderes at have klinisk fordel af fortsat behandling

The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This will be an open-label, non-randomised, multicentre, international study for eligible participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment as judged by the Investigator. Any clinical study conducted with benralizumab (Fasenra) for indications such as asthma, EGPA, HES and future indications from additional parent studies, is potentially a parent study.

Each participant continuing to receive clinical benefit from benralizumab but with no access to the drug after exiting the parent study must be seen at the Investigator site, offered the opportunity to transition to the ROSY-F. The duration of clinical benefit from study treatment for an individual participant can exceed the duration of a clinical trial. To ensure continued supply of treatment to a participant who, as judged by the Investigator, is still receiving benefit when he/she either completes or exits the parent study or when the parent study closes, a roll-over study is the most universally acceptable mechanism for continuing to provide ongoing study treatment.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

230

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Buenos Aires, Argentina, C1121ABE
        • Rekruttering
        • Research Site
      • Florida, Argentina, B1602DQD
        • Rekruttering
        • Research Site
      • Lobos, Argentina, 7240
        • Ikke rekrutterer endnu
        • Research Site
      • Mar del Plata, Argentina, B7600FYK
        • Rekruttering
        • Research Site
      • Mendoza, Argentina, 5500
        • Rekruttering
        • Research Site
      • Mendoza, Argentina, M5500
        • Rekruttering
        • Research Site
      • Rosario, Argentina, 2000
        • Rekruttering
        • Research Site
      • San Juan Bautista, Argentina, 1888
        • Ikke rekrutterer endnu
        • Research Site
      • Brussels, Belgien, 1070
        • Rekruttering
        • Research Site
      • Edegem, Belgien, B-2650
        • Ikke rekrutterer endnu
        • Research Site
    • Alberta
      • Calgary, Alberta, Canada, T2N 4N1
        • Ikke rekrutterer endnu
        • Research Site
    • Ontario
      • Hamilton, Ontario, Canada, L8N 4A6
        • Rekruttering
        • Research Site
      • Toronto, Ontario, Canada, M5G 1E2
        • Rekruttering
        • Research Site
      • Toronto, Ontario, Canada, M5G 1X8
        • Ikke rekrutterer endnu
        • Research Site
      • Toronto, Ontario, Canada, M5T 3A9
        • Rekruttering
        • Research Site
      • London, Det Forenede Kongerige, W2 1NY
        • Rekruttering
        • Research Site
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Ikke rekrutterer endnu
        • Research Site
    • Maryland
      • Bethesda, Maryland, Forenede Stater, 20892
        • Ikke rekrutterer endnu
        • Research Site
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48105
        • Ikke rekrutterer endnu
        • Research Site
    • New Jersey
      • Northfield, New Jersey, Forenede Stater, 08225
        • Ikke rekrutterer endnu
        • Research Site
    • New York
      • The Bronx, New York, Forenede Stater, 10459
        • Ikke rekrutterer endnu
        • Research Site
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27705
        • Ikke rekrutterer endnu
        • Research Site
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • Rekruttering
        • Research Site
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84107
        • Ikke rekrutterer endnu
        • Research Site
      • Bron, Frankrig, 69677
        • Ikke rekrutterer endnu
        • Research Site
      • Marseille, Frankrig, 13915
        • Rekruttering
        • Research Site
      • Montpellier, Frankrig, 34090
        • Rekruttering
        • Research Site
      • Nantes, Frankrig, 44093
        • Rekruttering
        • Research Site
      • Paris, Frankrig, 75014
        • Rekruttering
        • Research Site
      • Paris, Frankrig, 75018
        • Rekruttering
        • Research Site
      • Pessac, Frankrig, 33604
        • Rekruttering
        • Research Site
      • Suresnes, Frankrig, 92151
        • Rekruttering
        • Research Site
      • Rotterdam, Holland, 3015 GD
        • Ikke rekrutterer endnu
        • Research Site
      • Ahmedabad, Indien, 380052
        • Trukket tilbage
        • Research Site
      • Ajmer, Indien, 305001
        • Ikke rekrutterer endnu
        • Research Site
      • Haifa, Israel, 34362
        • Rekruttering
        • Research Site
      • Holon, Israel, 5822012
        • Rekruttering
        • Research Site
      • Petah Tikva, Israel, 492025
        • Ikke rekrutterer endnu
        • Research Site
      • Roma, Italien, 00165
        • Trukket tilbage
        • Research Site
      • Chęciny, Polen, 26-060
        • Ikke rekrutterer endnu
        • Research Site
      • Gdansk, Polen, 80-214
        • Ikke rekrutterer endnu
        • Research Site
      • Lodz, Polen, 90-302
        • Trukket tilbage
        • Research Site
      • Lodz, Polen, 90-153
        • Ikke rekrutterer endnu
        • Research Site
      • Incheon, Sydkorea, 400-711
        • Rekruttering
        • Research Site
      • Istanbul, Tyrkiet (Türkiye), 34093
        • Ikke rekrutterer endnu
        • Research Site
      • Innsbruck, Østrig, 6020
        • Ikke rekrutterer endnu
        • Research Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

6 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • 1. Provision of signed and dated written ICF.

    2. Participants completing minimum required OLE period of a parent study and judged by the Investigator to benefit from continued treatment.

  • 3. Participants must agree to follow the contraception requirements as per their respective parent protocols from study inclusion up to 12 weeks after the last dose of study treatment.

  • 4. Participants without childbearing potential at enrolment must agree to start appropriate contraception if childbearing potential develops during the study and up to 12 weeks after the last dose of study treatment.

  • 5. Participants who are unable to access commercially available benralizumab and clinically indicated for continuation.

Exclusion Criteria:

  • 1. Ongoing, unresolved AE requiring interruption of treatment at the end of the prior parent study (ie, when the parent study is either completed or closed) that in the Investigator's opinion would prevent restarting benralizumab.
  • 2. Participants who are planning to use live/live-attenuated vaccines.
  • 3. Participants who are planning to use biologic therapies, including B-cell therapies with the exception for the treatment of co-morbidities where no alternative medicine is available.
  • 4. Participants with any medical condition (such as cancer or viral infections [hepatitis]) or psychiatric condition that, in the opinion of the Investigator, could jeopardise or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments.
  • 5. Concurrently enrolled in any clinical study (other than a parent study).
  • 6. Participants who discontinued the parent study prior to completing the minimum OLE or treatment period.
  • 7. Local access to commercially available benralizumab.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Benralizumab arm

Benralizumab will be administrated as an subcutaneous injection at a frequency in line with that received in the parent study.

Accessorized Pre-Filled Syringe (Solution for injection).

Andre navne:
  • Fasenra

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumab
Tidsramme: From baseline until 8 weeks after the last dose of benralizumab

To provide benralizumab to participants who continue to benefit at the end of the parent clinical study while monitoring long-term safety and tolerability of benralizumab

From baseline until 8 weeks after the last dose of benralizumab

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

24. juli 2026

Primær færdiggørelse (Anslået)

27. december 2029

Studieafslutning (Anslået)

27. december 2029

Datoer for studieregistrering

Først indsendt

17. februar 2026

Først indsendt, der opfyldte QC-kriterier

27. februar 2026

Først opslået (Faktiske)

3. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • D3250N00036

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-delingsadgangskriterier

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.

Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .